TY - JOUR
AU1 - Carbone, Federico
AU2 - Bonaventura, Aldo
AU3 - Liberale, Luca
AU4 - Paolino, Sabrina
AU5 - Torre, Francesco
AU6 - Dallegri, Franco
AU7 - Montecucco, Fabrizio
AU8 - Cutolo, Maurizio
AB - Substantial epidemiological data identified cardiovascular (CV) diseases as a main cause of mortality in patients with rheumatoid arthritis (RA). In light of this, RA patients may benefit from additional CV risk screening and more intensive prevention strategies. Nevertheless, current algorithms for CV risk stratification still remain tailored on general population and are burdened by a significant underestimation of CV risk in RA patients. Acute CV events in patients with RA are largely related to an accelerated atherosclerosis. As pathophysiological features of atherosclerosis overlap those occurring in the inflamed RA synovium, the understanding of those common pathways represents an urgent need and a leading challenge for CV prevention in patients with RA. Genetic background, metabolic status, gut microbiome, and systemic inflammation have been also suggested as additional key pro-atherosclerotic factors. The aim of this narrative review is to update the current knowledge about pathophysiology of atherogenesis in RA patients and potential anti-atherosclerotic effects of disease-modifying anti-rheumatic drugs.
TI - Atherosclerosis in Rheumatoid Arthritis: Promoters and Opponents
JF - Clinical Reviews in Allergy & Immunology
DO - 10.1007/s12016-018-8714-z
DA - 2020-02-26
UR - https://www.deepdyve.com/lp/springer-journals/atherosclerosis-in-rheumatoid-arthritis-promoters-and-opponents-pVZ3AA36a6
SP - 1
EP - 14
VL - 58
IS - 1
DP - DeepDyve
ER -